L-107-2015
Agreement ID
L-107-2015
Lead IC
NCI
Exclusivity
Exclusive
External Party
Iovance Biotherapeutics. Inc.
Fiscal Year
2022
Territory
Worldwide
Execution Date
Effective Date
Export Date
Technologies
TAB-3993 Cancer Therapeutic Based on T Cell Receptors Designed to Regiospecifically Release Interleukin-12
TAB-4023 Improved Personalized Cancer Immunotherapy
TAB-3872 Tethered Interleukin-15 (IL-15)/IL-21 to Enhance T Cells for Cellular Therapy
TAB-4144 Potassium Hydroxy Citrate Promotes Longevity and Efficacy of Anti-Tumor T cells for Adoptive Cell Therapy (ACT)
TAB-3893 T-cell Phenotypes Associated with Clinical Response to Adoptive Immunotherapy
TAB-4326 Extremely Rapid Method to Isolate Neoantigen Reactive T Cell Receptors (TCRs)
TAB-4145 Method of Neoantigen-Reactive T Cell Receptor (TCR) Isolation from Peripheral Blood of Cancer Patients
TAB-4023 Improved Personalized Cancer Immunotherapy
TAB-3872 Tethered Interleukin-15 (IL-15)/IL-21 to Enhance T Cells for Cellular Therapy
TAB-4144 Potassium Hydroxy Citrate Promotes Longevity and Efficacy of Anti-Tumor T cells for Adoptive Cell Therapy (ACT)
TAB-3893 T-cell Phenotypes Associated with Clinical Response to Adoptive Immunotherapy
TAB-4326 Extremely Rapid Method to Isolate Neoantigen Reactive T Cell Receptors (TCRs)
TAB-4145 Method of Neoantigen-Reactive T Cell Receptor (TCR) Isolation from Peripheral Blood of Cancer Patients